In vitro and in vivo evaluation of positively charged liposaccharide derivatives as oral absorption enhancers for the delivery of anionic drugs

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2333-2342

  Bergeon, Julie A ^a   Ziora, Zyta M ^a   Abdelrahim, Adel S ^a   Pernevi, Niklas U ^a   Moss, Anne R ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Absorption enhancer; Bioavailability; Caco 2 cells; Calorimetry (ITC); Charged liposaccharide; Ion pairing; Oral drug delivery; Piperacillin

Indexed keywords

LIPOPOLYSACCHARIDE; PIPERACILLIN;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; ISOTHERMAL TITRATION CALORIMETRY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANIONS; ANTI-BACTERIAL AGENTS; CACO-2 CELLS; CALORIMETRY; CELL CULTURE TECHNIQUES; DRUG CARRIERS; DRUG STABILITY; ERYTHROCYTES; ESCHERICHIA COLI; HEMOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MOUTH MUCOSA; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STATIC ELECTRICITY; TANDEM MASS SPECTROMETRY;

EID: 77951265379     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21999     Document Type: Article

References (25)

1. Trapani A, Garcia-Fuentes M, Alonso MJ. 2008. Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19:185101-185110 (Pubitemid 351588178)
2. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. 2005. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: A target for drug delivery. Curr Drug Deliv 2:9-22 (Pubitemid 40590917)
3. Shaji J, Patole V. 2008. Protein and peptide drug delivery: Oral approaches. Indian J Pharm Sci 70: 269-277
4. Godin B, Touitou E. 2006. Enhancers for enteral delivery of macromolecules with emphasis on surfactants. In: Touitou E, Barry BW, editors. Enhancement in drug delivery. Boca Raton, FL (USA): CRC Press. pp. 37-56
5. Pouton CW, Porter CJH. 2008. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev 60:625-637
6. Wong A, Toth I. 2001. Lipid, sugar and liposaccharide based delivery systems. Curr Med Chem 8:1123-1136 (Pubitemid 32633662)
7. Bastin RJ, Bowker MJ, Slater BJ. 2000. Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org Process Res Dev 4:427-435
8. Neubert R. 1989. Ion-pair transport across membranes. Pharm Res 6:743-747
9. Falconer RA, Toth I. 2007. Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. Bioorg Med Chem 15:7012-7020 (Pubitemid 47470046)
10. Violette A, Cortes DAF, Bergeon JA, Falconer RA, Toth I. 2008. Optimized LC-MS/MS quantification method for the detection of piperacillin and application to the development of charged liposaccharides as oral penetration enhancers. Int J Pharm 351: 152-157 (Pubitemid 351186855)
11. Abdelrahim AS, Ziora ZM, Bergeon JA, Moss AR, Toth I. 2009. Synthesis and calorimetric titration of new glucolipopeptides as potential cationic penetration enhancers. Tetrahedron 65:9436-9442
12. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132
13. Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemoth 48:5-16
14. Nolting A, DallaCosta T, Rand KH, Derendorf H. 1996. Pharmacokinetic pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13:91-96 (Pubitemid 26076302)
15. Hoogkampkorstanje JAA, Westerdaal NAC. 1979. Activity and synergy of piperacillin and aminoglycosides against Pseudomonas- Aeruginiosa. Antonie Van Leeuwenhoek 45:617-618
16. Korvick JA, Yu VL. 1991. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother 35: 2167-2172
17. Pignatello R, Noce C, Campisi A, Acquaviva R, Bucolo C, Puglisi G, Toth I. 2007. Evaluation of cell tolerability of a series of lipoamino acids using biological membranes and a biomembrane model. Curr Drug Deliv 4:109-121 (Pubitemid 46557487)
18. Ross BP, Braddy AC, McGeary RP, Blanchfield JT, Prokai L, Toth I. 2004. Micellar aggregation and membrane partitioning of bile salts, fatty acids, sodium dodecyl sulfate, and sugarconjugated fatty acids: Correlation with hemolytic potency and implications for drug delivery. Mol Pharm 1:233-245
19. Amin K, Dannenfelser RM. 2006. In vitro hemolysis: Guidance for the pharmaceutical scientist. J Pharm Sci 95:1173-1176
20. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43 (Pubitemid 33653412)
21. BriskeAnderson MJ, Finley JW, Newman SM. 1997. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 214:248-257 (Pubitemid 27137482)
22. Donna AV. 2008. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci 97:712-725
23. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89:429-442
24. He X. 2009. Integration of physical, chemical, mechanical, and biopharmaceutical properties in solid oral dosage form development. In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter W, editors. Developing solid oral dosage forms - Pharmaceutical theory and practice. New-York, NY (USA): Elseviewer Inc. pp. 409-442
25. Rege BD, Yu LX, Husain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776-1786